Abstract:Interleukin (IL)-15-N72D superagonist-complexed with IL-15RαSushi-Fc fusion protein (IL-15SA/IL-15RαSu-Fc; ALT-803) has been reported to exhibit significant anti-tumor activity in murine myeloma, rat bladder cancer, and murine glioblastoma models. In this study, we examined the immunomodulatory and anti-tumor effects of IL-15SA/IL-15RαSu-Fc in tumor-free and highly metastatic tumor-bearing mice. Here, IL-15SA/IL-15RαSu-Fc significantly expanded natural killer (NK) and CD8+ T cells. In examining NK cell subsets, the greatest significant increase was in highly cytotoxic and migrating (CD11b+, CD27hi; high effector) NK cells, leading to enhanced function on a per-cell basis. CD8+ T cell subset analysis determined that IL-15SA/IL-15RαSu-Fc significantly increased IL-15 responding memory (CD122+, CD44+) CD8+ T cells, in particular those having the innate (NKG2D+, PD1-) phenotype. In 4T1 breast tumor-bearing mice, IL-15SA/IL-15RαSu-Fc induced significant anti-tumor activity against spontaneous pulmonary metastases, depending on CD8+ T and NK cells, and resulting in prolonged survival. Similar anti-tumor activity was seen in the experimental pulmonary metastasis model of CT26 colon carcinoma cells, particularly when IL-15SA/IL-15RαSu-Fc was combined with a cocktail of checkpoint inhibitors, anti-CTLA-4 and anti-PD-L1. Altogether, these studies showed for the first time that IL-15SA/IL-15RαSu-Fc (1) promoted the development of high effector NK cells and CD8+ T cell responders of the innate phenotype, (2) enhanced function of NK cells, and (3) played a vital role in reducing tumor metastasis and ultimately survival, especially in combination with checkpoint inhibitors.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the potential of IL - 15 super - agonist and IL - 15 receptor αSushi - Fc fusion complex (IL - 15SA/IL - 15RαSu - Fc; ALT - 803) as a cancer immunotherapy drug by studying its immunomodulatory and anti - tumor effects in tumor - free and highly metastatic tumor mice. Specifically, the research focuses on the following points: 1. **Immunomodulatory effect**: Evaluate the impact of IL - 15SA/IL - 15RαSu - Fc on natural killer cells (NK cells) and memory CD8+ T cell subsets, especially promoting the development of high - effector NK cells and memory CD8+ T cells with an innate phenotype. 2. **Antitumor activity**: Study the antitumor activity of IL - 15SA/IL - 15RαSu - Fc in 4T1 breast tumor and CT26 colon cancer models, especially its inhibitory effect on spontaneous lung metastasis. 3. **Combination therapy effect**: Explore the synergistic antitumor effect when IL - 15SA/IL - 15RαSu - Fc is used in combination with checkpoint inhibitors (such as anti - CTLA - 4 and anti - PD - L1). Through these studies, the paper aims to provide the basis for the potential application of IL - 15SA/IL - 15RαSu - Fc in the immunotherapy of highly metastatic cancers.

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas